Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Antithrombotic Therapy in Patients With Chronic Kidney Disease

Open access
Capodanno, Davide, Angiolillo, Dominick J. · 2012 · Circulation

Abstract

C hronic kidney disease (CKD) is a pandemic public health problem, with Ͼ500 million people worldwide estimated to have some form of kidney injury. 1 Survey data suggest that the prevalence of CKD in the United States has increased between 1988 to 1994 and 1999 to 2004 from 10% to 13%, reaching a rate of 14% in 2010.2,3 Overlapping conditions such as acute kidney injury play an important role in the growing epidemiology of CKD, and underlying CKD is in turn an important risk factor for acute kidney injury and end-stage renal disease.Key factors contributing to the increased prevalence of CKD include the aging population and the growing burden of diabetes mellitus.4 The prevalence of stage 3 or 4 CKD has been reported to be Ϸ38% for adults Ն70 years old versus Ϸ1% in adults 20 to 39 years of age.2,5 Patients with diabetes mellitus are found to present with CKD in about one third of cases, with diabetic nephropathy as the most common cause of renal impairment.6 Notably, numerous epidemiological studies have shown that patients with all stages of CKD experience higher rates of atherothrombotic disease manifestations and processes with thromboembolic potential such as atrial fibrillation than the general population.[7][8][9][10] This underscores the importance of antithrombotic treatment strategies in these patients.However, the risk-tobenefit ratio with antithrombotic therapies may be altered in CKD.In fact, patients with CKD also have an increased risk of bleeding complications.[11][12][13] Importantly, bleeding has emerged as an independent predictor of adverse outcomes, including mortality.14 -17 Moreover, patients with severe CKD are less likely to receive medications of proven benefit.18,19 Overall, these findings contribute to explain why patients with reduced renal function have poorer prognosis compared with patients with preserved renal function.Defining the fine balance between safety and efficacy remains a challenge in patients with CKD treated with antithrombotic therapy.Unfortunately, dosing errors, which commonly occur in patients with CKD, accounts for almost one third of adverse drug events, and more than half of these errors occur at the prescription stage.20 Therefore, understanding whether a drug should or should not be prescribed and individualizing dosage regimens are key to balancing the safety and efficacy profiles of antithrombotic medications in CKD patients.This article provides an overview of the currently available evidence on the use of antithrombotic therapy in patients with CKD.In particular, a description of thrombosis and hemostatic profiles that characterize CKD patients, considerations for use of antithrombotic agents, including antiplatelet and anticoagulant therapies, and a review of the safety and efficacy data in CKD patients in the settings of coronary artery disease manifestations and atrial fibrillation are provided.A discussion of antithrombotic therapy in patients with acute kidney injury and end-stage renal disease is beyond the scope of this article. CKD: DefinitionsThe Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation defines CKD as either kidney damage or a decreased kidney glomerular filtration rate (GFR) of Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 for Ն3 months.21 The different stages of CKD are listed in Table 1.While stages 3 through 5 are characterized by a gradient of GFR ranges, markers of structural or functional kidney damage other than GFR, including blood, urine, or imaging tests abnormalities, need to be present to establish a diagnosis of stage 1 and stage 2 CKD.Kidney failure is defined as either a GFR of Ͻ15 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 or a need for initiation of kidney replacement therapy (dialysis or transplantation).End-stage renal disease is a US administrative definition that includes patients treated by dialysis or transplantation regardless of the GFR level.Many calculators are available to estimate the GFR.The National Kidney Foundation recommends using the Modification of Diet in Renal Disease equation.22 Thrombosis and Hemostasis: Biological Considerations in Patients With CKDPatients with CKD may present with platelet dysfunction and abnormalities in the enzymatic coagulation cascade.This may explain why patients with CKD may experience 2 opposite hemostatic complications: bleeding diathesis and thrombotic tendencies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.084996

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 165

Metadata

Authors
Capodanno, D., & Angiolillo, D. J.
Venue
Circulation
Published
2012-05-29
Volume
125
Issue
21
Pages
2649-2661
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2061089824
Cited by
165
References
12
FWCI
7.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antithrombotic Therapy in Patients With Chronic Kidney Disease. https://app.cochat.ai/papers/10.1161/circulationaha.111.084996
The paper
Capodanno, D., & Angiolillo, D. J. (2012). Antithrombotic Therapy in Patients With Chronic Kidney Disease. Circulation. https://doi.org/10.1161/circulationaha.111.084996

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.